Semaglutide research highlights cardiovascular benefits and lean mass preservation

New research suggests that semaglutide, a GLP-1 receptor agonist used for weight loss, may provide cardiovascular benefits that extend beyond simple weight reduction. An analysis of the SELECT clinical trial, led by Professor Helen Colhoun of the University of Edinburgh, found that while semaglutide reduces the risk of serious heart disease, only half of this reduction can be attributed to changes in traditional risk factors like body weight, waist circumference, and blood pressure.

In a separate study published in the Proceedings of the National Academy of Sciences, researchers at Northwestern University investigated ways to mitigate the loss of lean mass often associated with semaglutide-induced weight loss. Using mice, the team tested an experimental RNA treatment designed to reduce the activity of the ZFP423 gene. This treatment aims to encourage white fat to adopt the energy-burning characteristics of beige fat.

The combination of the RNA treatment and semaglutide resulted in mice losing approximately 5.5% of their lean mass, compared to a 10% loss in mice receiving semaglutide alone. These mice also showed improved sugar handling and greater reductions in total body fat.